ALAMEDA, CA – Sep 30, 2015 — AllCells, LLC, (the “company”) a leading provider of hematologic tissue, primary cell products, and Bioservices that support life science research applications worldwide, today announced its Clinical Division, LeukoLab, received Institutional Review Board (IRB) approval to administer vaccines to clinically healthy human donors.
As part of its expanded service offering LeukoLab is now able to vaccinate adult volunteer donors with vaccines such as Influenza (Flu), Human Papillomavirus (HPV), Pneumococcal, and Hepatitis B. “This new IRB approval allows LeukoLab to complete whole blood collections from qualified human donors pre and post-vaccination, and at various time intervals so that vaccine developers can better study kinetics of an individual’s immune response”, commented Sheila Smith, RN, BSN, HP (ASCP), Clinical Operations Manager of LeukoLab.
AllCells delivers hematologic tissue collected via LeukoLab directly to scientific researchers located around the world, or such tissue can be immediately processed in the company’s cell manufacturing laboratory to produce highly purified hematology and immunology primary cell types which are characterized and packaged according to customer specifications.
Wayne Vaz, the company’s Vice President, Corporate & Business Development commented “We’re seeing growing industry demand towards project customization on multiple levels — for example, custom tissue procurement from donors having certain profiles of interest, donor screening based upon predefined exclusion and inclusion criteria such as human leukocyte antigen (HLA) type, blood type, expanded viral panel screening, vaccination history, age, gender, ethnicity, and other characteristics researchers identify as being especially relevant to their drug discovery and vaccine development efforts. As a value-added service our Bioservices team often collaborates with researchers to design and perform various types of custom cell-based assays utilizing these fresh isolated primary cells”.
LeukoLab maintains a sizeable database of human donors and this repository is constantly increasing. Researchers with an interest in LeukoLab’s vaccination and blood collection services may contact the company for more information at P 1-888 535 3444, P 1-501-521-2600, and email@example.com.
About AllCells, LLC
AllCells (www.allcells.com) is a biotechnology company founded in 1998 to provide global researchers with a reliable supply of biologically relevant, consistent quality primary cells (healthy & diseased) which enable the advancement of scientific research in the areas of cell biology, oncology, virology, hematology, infectious disease, stem cell research, and development of tissue, cell, and gene therapies. Unlike cell lines, which are typically mutated, transformed or immortalized, primary cells retain their original phenotypes hence better reflect in vivo morphology, metabolism and growth characteristics. These attributes are especially important for in vitro research applications in which in vivo-like models are critically important. By partnering with AllCells, investigators can dramatically reduce the time needed to isolate cells with guaranteed consistency, thereby improving the efficiency, accuracy and relevance of their research studies. AllCells is fully certified in accordance with local, state and federal requirements.
Wayne E. Vaz
Corporate & Business Development
P 603 490 7992